Clinical value of first-morning urine exfoliated cell HPV detection in the diagnosis of high-grade cervical lesions
-
By
-
Fang Li
-
Lihua Pei
-
Juan Lv
-
Mingfu Jiang
-
Hui Yang
-
Hailan Ma
-
Ning Zhou
-
Lingfei Li
-
Ying Luo
-
Zhengfu Wang
-
Haifeng Jiang
-
Na Zhao
-
July 8, 2026
-
Clinical Scorecard: Diagnostic Significance of First-Morning Urine HPV Testing for Identifying High-Grade Cervical Lesions
At a Glance
| Category | Detail |
|---|
| Condition | Cervical Cancer Screening |
| Key Mechanisms | First-morning urine (FMU) HPV testing detects HPV DNA from cervical-origin exfoliated cells. |
| Target Population | Women attending gynecology and colposcopy clinics in Ningxia, China. |
| Care Setting | Multicenter diagnostic accuracy study in healthcare institutions. |
Key Highlights
- FMU HPV testing shows sensitivity of 90.50% and specificity of 67.00% for CIN2+ detection.
- Higher patient compliance (97.20%) and satisfaction (95.40%) with FMU compared to traditional testing.
- CIN2+ prevalence in the study cohort was 40%, reflecting a disease-enriched design.
Guideline-Based Recommendations
Diagnosis
- Use FMU HPV testing as a complementary method for detecting high-grade cervical lesions.
Management
- Colposcopy and biopsy for patients with abnormal co-testing results.
Monitoring & Follow-up
- Regular screening programs to ensure early detection of cervical lesions.
Risks
- Untreated high-grade lesions may progress to invasive cancer in 30–50% of cases.
Patient & Prescribing Data
Women with varying degrees of cervical lesions, including high-grade lesions.
FMU HPV testing is a non-invasive alternative that may improve screening participation.
Clinical Best Practices
- Implement FMU HPV testing protocols in diverse healthcare settings.
- Ensure informed consent and ethical compliance in screening programs.
Related Resources & Content
